Korean companies in mRNA link-up on COVID-19 vaccine and more

10 June 2021

mCureX, a subsidiary of RNAi company OliX Pharmaceuticals (Kosdaq: 226950), has signed deals with Samyang Holdings (KRX: 000070) to advance development of a mRNA vaccine for COVID-19, and with GC Pharma (KRX: 006280) to develop mRNA vaccines and therapeutics for respiratory infections and other diseases.

Under the agreement with Samyang Holdings, the companies will develop an mRNA vaccine for COVID-19, leveraging Samyang’s drug delivery system (DDS) which is designed to protect nucleic acids, like mRNA, that are susceptible to degradation by certain enzymes in the human body.

"Vaccines and therapeutics based on mRNA hold great promise in preventing and treating human diseases given their relatively short development timelines"The DDS is based on proprietary bioabsorbable polymer technology that enables therapeutics to be safely and effectively delivered into the human body. mCureX, in collaboration with Samyang Holdings, is developing a COVID-19 vaccine that will effectively target viral variants.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK